Entero Healthcar

Why is Entero Healthcare Solutions Ltd falling/rising?

As of 11-Jun, Entero Healthcare Solutions Ltd's stock price is at 1,118.35, reflecting a decline of 1.67%. The stock is on a downward trend, trading below key moving averages, with a year-to-date increase of 9.02% but a year-over-year decline of 7.37%.

As of 11-Jun, Entero Healthcare Solutions Ltd's stock price is falling, currently at 1,118.35, which reflects a decrease of 19.0 points or 1.67%. The stock has been on a downward trend, having lost 1.75% over the last two days. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish momentum. <BR><BR>In the past week, the stock has declined by 1.94%, while over the past month, it has experienced a more significant drop of 9.08%. Despite a year-to-date increase of 9.02%, the stock's performance over the last year shows a decline of 7.37%, which is worse than the benchmark Sensex's decline of 10.52%. <BR><BR>However, there are some positive indicators, such as a strong ability to service debt with a low Debt to EBITDA ratio of 2.55 times and healthy long-term growth in net sales and operating profit. The company has also reported positive results for the last nine consecutive quarters. Despite these strengths, the current market sentiment appears to be negative, contributing to the stock's decline.

What does Entero Healthcar do?

Entero Healthcare Solutions Ltd is a small-cap retail company, incorporated in 2018, with net sales of 1,910 Cr and a net profit of 28 Cr as of March 2026. Key financial metrics include a P/E ratio of 40.00 and a market cap of INR 5,035 Cr.

Overview:<BR>Entero Healthcare Solutions Ltd operates in the retailing industry and is classified as a small-cap company.<BR><BR>History:<BR>The company was incorporated in 2018 as Entero Healthcare Solutions Private Limited and later converted into a public limited company, changing its name to Entero Healthcare Solutions Limited. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,910 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 28 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 5,035 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 40.00<BR>- Industry P/E: 20<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.23<BR>- Return on Equity: 7.22%<BR>- Price to Book: 3.00<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Which are the latest news on Entero Healthcar?

How big is Entero Healthcar?

As of 10th June, Entero Healthcare Solutions Ltd has a market capitalization of 5,035.00 Cr and reported net sales of 6,591.22 Cr and a net profit of 115.04 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Entero Healthcare Solutions Ltd has a market capitalization of 5,035.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 6,591.22 Cr, while the sum of Net Profit for the same period is 115.04 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 1,724.14 Cr, and Total Assets amount to 2,688.21 Cr.

Who are the peers of the Entero Healthcar?

Entero Healthcar's peers include A B Lifestyle, Medplus Health, Aditya Vision, Khemani Distrib., M K Exim India, Novelix Pharma, Purple United, Silgo Retail, and Magson Retail. Entero Healthcar has average management risk and growth, with a 1-year return of -6.21%, outperforming M K Exim India but underperforming Novelix Pharma, which has the highest return at 153.02%.

Peers: The peers of Entero Healthcar are A B Lifestyle, Medplus Health, Aditya Vision, Khemani Distrib., M K Exim India, Novelix Pharma, Purple United, Silgo Retail, and Magson Retail.<BR><BR>Quality Snapshot: Excellent management risk is observed at Aditya Vision, Khemani Distrib., M K Exim India, and Purple United, while Average management risk is found at Entero Healthcar and A B Lifestyle. Below Average management risk is present at Medplus Health and Novelix Pharma. For growth, Excellent growth is noted at Aditya Vision, Medplus Health, Entero Healthcar, and Purple United, while Below Average growth is seen at A B Lifestyle, Khemani Distrib., M K Exim India, and Silgo Retail. Average growth is reported for Novelix Pharma and Magson Retail. In terms of capital structure, Excellent capital structure is attributed to M K Exim India, Good capital structure is observed at Entero Healthcar, Khemani Distrib., and Silgo Retail, while Below Average capital structure is found at A B Lifestyle, Medplus Health, Novelix Pharma, Purple United, and Magson Retail.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Novelix Pharma at 153.02%, while the lowest is M K Exim India at -25.20%. Entero Healthcar's 1-year return is -6.21%, which is higher than M K Exim India but lower than Novelix Pharma. Additionally, Khemani Distrib., M K Exim India, and Magson Retail have negative six-month returns.

Should I buy, sell or hold Entero Healthcare Solutions Ltd?

Are Entero Healthcare Solutions Ltd latest results good or bad?

Entero Healthcare Solutions Ltd's latest results show strong revenue growth with a 42.63% year-on-year increase in net sales, reaching ₹1,909.93 crores. However, profit growth is modest at 9.03%, raising concerns about margin sustainability and cost management.

Entero Healthcare Solutions Ltd's latest results present a mixed picture. On the positive side, the company achieved a significant increase in net sales, with a sequential growth of 11.92% and a remarkable year-on-year growth of 42.63%, reaching an all-time high of ₹1,909.93 crores in Q4 FY26. This reflects strong operational momentum and effective scaling of its business.<BR><BR>However, the growth in net profit was less impressive, with only a 1.38% increase quarter-on-quarter and a modest 9.03% year-on-year growth, totaling ₹28.01 crores. This slower profit growth raises concerns about margin sustainability and cost management, particularly as the profit after tax margin remains relatively low at 2.36%. Additionally, rising interest costs and increased depreciation charges have further pressured profitability.<BR><BR>Overall, while Entero Healthcare demonstrates strong revenue growth and improved operating margins, the challenges in translating this growth into substantial profit gains suggest caution regarding the sustainability of its current performance. The results indicate that while the company is expanding, it faces significant operational hurdles that need to be addressed to enhance profitability.

When is the next results date for Entero Healthcare Solutions Ltd?

The next results date for Entero Healthcare Solutions Ltd is 25 May 2026.

The next results date for Entero Healthcare Solutions Ltd is scheduled for 25 May 2026.

Is Entero Healthcar technically bullish or bearish?

As of November 19, 2025, Entero Healthcare's technical trend is bearish with moderate strength, indicated by bearish MACD, Bollinger Bands, moving averages, and KST, despite mixed signals from Dow Theory.

As of 19 November 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly timeframe, bearish signals from Bollinger Bands on both weekly and monthly timeframes, and bearish moving averages on the daily timeframe. Additionally, the KST is bearish on the weekly, and the OBV shows a mildly bearish trend on the monthly. The Dow Theory reflects a mildly bullish stance on the weekly but is mildly bearish on the monthly, indicating mixed signals. Overall, the prevailing bearish indicators suggest a negative outlook for Entero Healthcare.

Is Entero Healthcar overvalued or undervalued?

As of November 14, 2025, Entero Healthcare is considered very attractive and undervalued with a PE ratio of 44.13 and a PEG ratio of 0.31, despite a challenging year-to-date return of -20.6%, indicating strong growth potential compared to its peers.

As of 14 November 2025, Entero Healthcare has moved from an attractive to a very attractive valuation grade. The company is currently considered undervalued, with a PE ratio of 44.13, an EV to EBITDA of 23.43, and a PEG ratio of 0.31, indicating strong growth potential relative to its price. <BR><BR>In comparison to its peers, Entero's PE ratio significantly exceeds that of TCS at 22.34 and Infosys at 22.19, while its EV to EBITDA is higher than TCS's 15.7 but lower than that of LTI Mindtree at 23.98. Despite a challenging year with a year-to-date return of -20.6% compared to the Sensex's 8.22%, Entero Healthcare's strong valuation metrics suggest it remains an attractive investment opportunity in the retailing sector.

How has been the historical performance of Entero Healthcar?

Entero Healthcar has shown significant growth over the past five years, with net sales increasing from 1,779.74 Cr in March 2021 to 5,095.78 Cr in March 2025, and profit after tax turning positive at 107.43 Cr. The company has improved its operating profit and total assets while achieving a net cash inflow from investing activities in March 2025.

Answer:<BR>The historical performance of Entero Healthcar shows significant growth over the past five years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Entero Healthcar's net sales have increased from 1,779.74 Cr in March 2021 to 5,095.78 Cr in March 2025, reflecting a strong upward trend. Total operating income has followed a similar trajectory, rising from 1,779.74 Cr to 5,095.78 Cr during the same period. The company's total expenditure, excluding depreciation, has also grown, reaching 4,924.23 Cr in March 2025, up from 1,758.19 Cr in March 2021. Operating profit, excluding other income, has improved significantly, moving from 21.55 Cr in March 2021 to 171.55 Cr in March 2025. This growth in operating profit has contributed to a profit before tax of 138.74 Cr in March 2025, a substantial increase from the losses recorded in previous years. The profit after tax has turned positive, reaching 107.43 Cr in March 2025, compared to losses in earlier years. The company's total assets have increased from 748.97 Cr in March 2020 to 2,688.21 Cr in March 2025, while total liabilities have also risen, from 748.97 Cr to 2,688.21 Cr. Cash flow from operating activities has shown negative trends, but cash flow from investing activities has turned positive in March 2025, indicating a net cash inflow of 81.00 Cr. Overall, Entero Healthcar has demonstrated a remarkable recovery and growth in its financial performance over the past five years.

Who are the top shareholders of the Entero Healthcar?

The top shareholders of Entero Healthcare include Orbimed Asia III Mauritius Limited with 38.01%, 70 foreign institutional investors holding 19.92%, and Surbhi Singh of the Prasid Uno Family Trust with 10.46%. Additionally, mutual funds hold 6.09%, while individual investors own 5.41% of the company.

The top shareholders of Entero Healthcare include several key players. The majority of the shares are held by promoters, with Orbimed Asia III Mauritius Limited being the largest individual promoter, holding 38.01%. Additionally, there are 70 foreign institutional investors (FIIs) collectively holding 19.92% of the shares. Mutual funds have a presence as well, with 7 schemes holding 6.09%. Among public shareholders, Surbhi Singh, representing the Prasid Uno Family Trust, is the largest, holding 10.46%. Individual investors collectively own 5.41% of the company.

Has Entero Healthcar declared dividend?

No Dividend History Available